Even with these theoretical concerns on the impact of appetite suppression, and a category of cognitive neuropathology, nascent data have indicated that GLP-1 RAs appear to be well tolerated in AD populations, showing very minor CNS-related adverse events in short- and medium-duration trials [66]. Here, GLP1R is linked to Alzheimer disease.